Shares Magazine
0.83p+0.00 (+0.00%)26 Apr 2024, 13:35
Jump to:
Ovoca Bio PLC Fundamentals
| Company Name | Ovoca Bio PLC | Last Updated | 2024-04-26 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 81.564 m | Market Cap | £672,901.40 |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -€0.07 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0 | Debt Equity Ratio | 0 |
| Asset Equity Ratio | 1.1622 | Cash Equity Ratio | 0.5537 |
| Quick Ratio | 3.6720 | Current Ratio | 3.70 |
| Price To Book Value | 0.1551 | ROCE | 0 |
Ovoca Bio PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Ovoca Bio PLC Company Financials
| Assets | 2022 | 2021 |
|---|---|---|
| Tangible Assets | 0 | €18,000.00 |
| Intangible Assets | €4.43 m | €5.78 m |
| Investments | 0 | €1.95 m |
| Total Fixed Assets | €4.43 m | €7.75 m |
| Stocks | €43,000.00 | €94,000.00 |
| Debtors | €1.22 m | €319,000.00 |
| Cash & Equivalents | €3.70 m | €6.59 m |
| Other Assets | 0 | 0 |
| Total Assets | €9.40 m | €14.77 m |
| Liabilities | 2022 | 2021 |
|---|---|---|
| Creditors within 1 year | €1.77 m | €1.34 m |
| Creditors after 1 year | 0 | 0 |
| Other Liabilities | €214,000.00 | 0 |
| Total Liabilities | €1.77 m | €1.34 m |
| Net assets | €7.63 m | €13.43 m |
| Equity | 2022 | 2021 |
|---|---|---|
| Called up share capital | €11.06 m | €11.06 m |
| Share Premium | 0 | 0 |
| Profit / Loss | -€5.61 m | -€5.25 m |
| Other Equity | €7.63 m | €13.43 m |
| Preference & Minorities | 0 | 0 |
| Total Capital Employed | €7.63 m | €13.43 m |
| Ratios | 2022 | 2021 |
|---|---|---|
| Debt Ratio | 0 | 0 |
| Debt-to-Equity | 0 | 0 |
| Assets / Equity | 1.1622 | 1.1622 |
| Cash / Equity | 0.5537 | 0.5537 |
| EPS | -€0.06 | -€0.06 |
| Cash Flow | 2022 | 2021 |
|---|---|---|
| Cash from operating activities | -€5.16 m | -€4.38 m |
| Cashflow before financing | -€4.26 m | -€4.38 m |
| Increase in Cash | -€2.89 m | -€4.15 m |
| Income | 2022 | 2021 |
|---|---|---|
| Turnover | 0 | 0 |
| Cost of sales | 0 | 0 |
| Gross Profit | 0 | 0 |
| Operating Profit | -€5.58 m | -€5.33 m |
| Pre-Tax profit | -€5.61 m | -€5.25 m |
Ovoca Bio PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Ovoca Bio PLC is a life science investment company. The company is engaged in investing in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. The group has two business segments, bio-pharmaceutical and investment, which are operated principally in Russian Federation and investment activities operated from Bermuda, and with administrative activities in the Republic of Ireland. Its product candidate includes IVIX- Libicore - a novel synthetic peptide, administrated through a nasal spray. |
| Latest Interim Date | 28 Sep 2023 |
| Latest Fiscal Year End Date | 30 Jun 2022 |
Ovoca Bio PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2011-08-09 | Mr. John O'Connor | Non-Executive Director |
| 2021-11-04 | Mr. Leonid Pavlovich Skoptsov | Non-Executive Director |
| 2011-08-09 | Mr. Roger William Turner | Non-Executive Director |
| 2011-08-09 | Mr. Rowan Maule | Non-Executive Director |
| 2019-07-26 | Mr. Yuri Ivanovich Radchenko | Non-Executive Director |
| 2020-09-28 | Mr. Mikhail Alexandrovich Mogutov | Executive Director,Chairman |
| 2023-06-30 | Mr. Timothy Rand McCutcheon | Non-Executive Director |
| 2018-08-09 | Mr. Donald Schissel | Non-Executive Director |
| 2023-06-30 | Mr. Kirill Andreyevich Golovanov | Executive Director,Chairman (Interim) and Chief Executive Officer |
| 2011-08-09 | Mr. Guido Edward Maria Pas BEd | Non-Executive Director |
| 2011-08-09 | Mr. Richard O'Shea | Non-Executive Director |
| 2011-08-09 | Dr. Barrie Williams Oakes, M. Sc. | Non-Executive Director |
| 2018-08-09 | Mr. Kenneth Kuchling | Non-Executive Director |
| 2021-12-30 | Mr. Romulo Colindres | Non-Executive Director |
| 2019-08-28 | Mr. Nikolay Myasodev | Non-Executive Director |
| 2022-01-31 | Mr. Christopher Wiltshire | Executive Director,Chief Business Officer |
Ovoca Bio PLC Contact Details
| Company Name | Ovoca Bio PLC |
|---|---|
| Address | c/o OBH Partners, 17 Pembroke Street Upper, Dublin 2, D02 AT22 |
| Telephone | +353 17755600 |
| Website | https://www.ovocabio.com |
Ovoca Bio PLC Advisors
| Solicitor | OBH Partners |
|---|---|
| Phone | +353 17755600 |
| Fax | +353 17755601 |
| Stockbroker | Davy Corporate Finance |
|---|---|
| Phone | +353 16797788 |
| Fax | +353 16148727 |
| Bank | Allied Irish Bank |
|---|
| Registrar | Computershare Investor Services (Ireland) Ltd |
|---|---|
| Phone | +353 12163100 |
| Fax | +353 12163150 |
| Nominated Adviser | Davy Corporate Finance |
|---|---|
| Phone | +353 16797788 |
| Fax | +353 16148727 |
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Darktrace PLC | 602.00 | 16.44 |
| Travis Perkins PLC | 766.00 | 6.46 |
| Natwest Group PLC | 307.40 | 6.07 |
| Ashtead Group PLC | 6,104.00 | 5.97 |
| Tritax Eurobox PLC | 53.80 | 4.87 |
| Tbc Bank Group PLC | 3,450.00 | 4.39 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Convatec Group PLC | 257.80 | -6.46 |
| Wh Smith PLC | 1,120.00 | -5.25 |
| Beazley PLC | 638.00 | -3.11 |
| Entain PLC | 784.20 | -3.09 |
| Me Group International PLC | 162.80 | -2.75 |
| Ocado Group PLC | 353.10 | -2.54 |
Risers/fallers data from previous trading day.